Showing results (141-150 of 481) with videos related to
Sort By:
Pageof 49
JAMA Cardiology|August 24, 2017
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular DiseaseGregg C Fonarow, Anthony C Keech, Terje R Pedersen, et al.Circulation|April 19, 2006
Prevalence and determinants of troponin T elevation in the general populationThomas W Wallace, Shuaib M Abdullah, Mark H Drazner, et al.European Heart Journal|June 30, 2007
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG studyBenjamin M Scirica, David A Morrow, Zygmunt Sadowski, et al.American Heart Journal|June 24, 2010
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28Matthew W Sherwood, David A Morrow, Benjamin M Scirica, et al.JAMA Cardiology|December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial DataArman Qamar, Robert P Giugliano, Anthony C Keech, et al.Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.JAMA Cardiology|August 14, 2020
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical TrialPrakash Deedwania, Sabina A Murphy, Andre Scheen, et al.Clinical Cardiology|March 5, 2015
Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin TJonathan Grinstein, Marc P Bonaca, Petr Jarolim, et al.Journal of the American College of Cardiology|July 11, 2002
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studiesJames A de Lemos, David A Morrow, C Michael Gibson, et al.European Heart Journal|November 11, 2022
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54Marc P Bonaca, KyungAh Im, Giulia Magnani, et al.Pageof 49